Highest-materiality recent filing
Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend
Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).
Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out
Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.
Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42
GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend
Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.
Bio-Techne authorizes $500M share repurchase program, replacing prior 2022 authorization
Board authorized up to $500M in common stock repurchases on April 30, 2025.
Bio-Techne ordered to pay former CEO $35.98M over option expiration error
Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.
Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend
Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.
Bio-Techne grants CFO James Hippel 34,634 RSUs to correct forfeited options
Grant date: October 30, 2024; vesting in three equal annual installments.
Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend
Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.
Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)
Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.
Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.
Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors
Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).
Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.
Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024
Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.
On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.
On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.
Max materiality 0.80 · Median 0.60 · Most common event earnings